News about Clinical Trials

Novo's Denecimig Tolerable After Switch From Emicizumab

Novo's denecimig shows tolerability after switching from emicizumab in the FRONTIER5 hemophilia A study, published in Journal of Thrombosis and Haemostasis.

Clinical Trials | 19/09/2026 | By News Bureau

Roche's Lunsumio Combo Meets Phase 3 CELESTIMO Endpoint

Roche’s Phase 3 CELESTIMO study shows statistically significant, clinically meaningful improvement in PFS with Lunsumio plus lenalidomide in R/R follicular lymphoma.

Clinical Trials | 18/09/2026 | By News Bureau

Sobi-Innate Pharma Partnership Advances Lacutamab Phase 3 Study

The partnership between Sobi and Innate Pharma will support the TELLOMAK-3 confirmatory Phase 3 trial in CTCL and development of lacutamab in Sézary syndrome.

Clinical Trials | 18/09/2026 | By News Bureau

Arrowhead Pharma Reports Interim Data on Dual RNAi Therapy

Arrowhead Pharmaceuticals has announced interim topline clinical data for the first dual-functional RNAi therapeutic for the treatment of mixed hyperlipidemia.

Clinical Trials | 17/09/2026 | By News Bureau

AstraZeneca, Daiichi Sankyo's Enhertu Shows Superior PFS in First-Line HER2-Mutant NSCLC

DESTINY-Lung04 results showed Enhertu delivered a median PFS of 14.3 months versus 8.3 months with pembrolizumab plus chemotherapy in first-line HER2-mutant advanced NSCLC.

Clinical Trials | 16/09/2026 | By News Bureau

Ris-Rez Cuts Risk of Death by 54 Percent vs Topotecan in Relapsed SCLC in China

Ris-Rez reduced the risk of death by 54 percent versus topotecan in relapsed SCLC in China, extending median overall survival to 18.5 months versus 10.3 months with comparator.

Clinical Trials | 15/09/2026 | By News Bureau

BioNTech and OncoC4 Report Survival Benefit with Gotistobart in Squamous NSCLC

BioNTech and OncoC4 report updated phase 3 data showing gotistobart improved median Overall Survival (OS) to 18.5 months versus 10 months with chemotherapy in previously treated squamous NSCLC.

Clinical Trials | 14/09/2026 | By News Bureau |  114

Adneuris Presents New Cebranopadol Data for Acute Pain Treatment

Adneuris presents new cebranopadol data showing lower abuse potential and positive phase 3 ALLEVIATE results for moderate-to-severe acute pain.

Clinical Trials | 14/09/2026 | By News Bureau

BioMarin Reports Positive Phase 3 VOXZOGO Results in Hypochondroplasia

BioMarin reports positive phase 3 VOXZOGO results in children with hypochondroplasia, showing significant improvements in growth measures and supporting Food and Drug Administration (FDA) supplemental New Drug Application (sNDA).

Clinical Trials | 11/09/2026 | By News Bureau

Imfinzi-Tarlatamab Combination Improves Overall Survival in Phase 3 ES-SCLC Trial

AstraZeneca and Amgen reported statistically significant improvements in overall and progression-free survival with Imfinzi plus tarlatamab versus Imfinzi alone in the Phase 3 DeLLphi-305 trial.

Clinical Trials | 10/09/2026 | By News Bureau